|
1
|
Jurisic V, Radenkovic S and Konjevic G:
The actual role of LDH as tumor marker, biochemical and clinical
aspects. Adv Exp Med Biol. 867:115–124. 2015.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Chen XY, He C, Han DD, Zhou M, Wang Q,
Tian J, Li L, Xu F, Zhou E and Yang K: The predictive value of
Ki-67 before neoadjuvant chemotherapy for breast cancer: A
systematic review and meta-analysis. Future Oncol. 13:843–857.
2017.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Erić I, Petek Erić A, Kristek J, Koprivčić
I and Babić M: Breast cancer in young women: Pathologic and
immunohistochemical features. Acta Clin Croat. 57:497–502.
2018.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Li JB and Jiang ZF: Update and
interpretation of 2019 guideline of Chinese Society of clinical
oncology (CSCO): Breast cancer. Chin J Surg Oncol. 11:155–160.
2019.
|
|
5
|
Shet T: Ki-67 in breast cancer: Simulacra
and simulation. Indian J Cancer. 57:231–233. 2020.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Teichgraeber DC, Guirguis MS and Whitman
GJ: Breast cancer staging: Updates in the AJCC cancer staging
manual, 8th edition, and current challenges for radiologists, from
the AJR special series on cancer staging. AJR Am J Roentgenol.
217:278–290. 2021.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Guideline Recommendations for HER2
Detection in Breast Cancer Group. Guidelines for HER2 detection in
breast cancer, the 2014 version. Zhonghua Bing Li Xue Za Zhi.
43:262–267. 2014.PubMed/NCBI(In Chinese).
|
|
8
|
Gerdes J, Schwarting R and Stein H: High
proliferative activity of Reed Sternberg associated antigen Ki-1
positive cells in normal lymphoid tissue. J Clin Pathol.
39:993–997. 1986.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Goldhirsch A, Winer EP, Coates AS, Gelber
RD, Piccart-Gebhart M, Thürlimann B and Senn HJ: Panel members.
Personalizing the treatment of women with early breast cancer:
Highlights of the St Gallen international expert consensus on the
primary therapy of early breast cancer. Ann Oncol. 24:2206–2223.
2013.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Nishimura R, Osako T, Nishiyama Y, Tashima
R, Nakano M, Fujisue M, Toyozumi Y and Arima N: Prognostic
significance of Ki-67 index value at the primary breast tumor in
recurrent breast cancer. Mol Clin Oncol. 2:1062–1068.
2014.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Pathmanathan N, Balleine RL, Jayasinghe
UW, Bilinski KL, Provan PJ, Byth K, Bilous AM, Salisbury EL and
Boyages J: The prognostic value of Ki67 in systemically untreated
patients with node-negative breast cancer. J Clin Pathol.
67:222–228. 2014.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Kurozumi S, Matsumoto H, Hayashi Y, Tozuka
K, Inoue K, Horiguchi J, Takeyoshi I, Oyama T and Kurosumi M: Power
of PgR expression as a prognostic factor for
ER-positive/HER2-negative breast cancer patients at intermediate
risk classified by the Ki67 labeling index. BMC Cancer.
17(354)2017.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Kadivar M and Aram F: Assessment of Ki67
in breast cancer: A comparison between the Eye-10 method, stepwise
counting strategy, and international system of Ki67 evaluation.
Iran J Pathol. 15:13–18. 2020.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Urruticoechea A, Smith IE and Dowsett M:
Proliferation marker Ki-67 in early breast cancer. J Clin Oncol.
23:7212–7220. 2005.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Stuart-Harris R, Caldas C, Pinder SE and
Pharoah P: Proliferation markers and survival in early breast
cancer: A systematic review and meta-analysis of 85 studies in
32,825 patients. Breast. 17:323–334. 2008.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Fulawka L and Halon A: Ki-67 evaluation in
breast cancer: The daily diagnostic practice. Indian J Pathol
Microbiol. 60:177–184. 2017.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Dowsett M, Nielsen TO, A'Hern R, Bartlett
J, Coombes RC, Cuzick J, Ellis M, Henry NL, Hugh JC, Lively T, et
al: Assessment of Ki67 in breast cancer: recommendations from the
international Ki67 in breast cancer working group. J Natl Cancer
Inst. 103:1656–1664. 2011.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Ašoklis R, Kadziauskienė A, Paulavičienė
R, Petroška D and Laurinavičius A: Quantitative histopathological
assessment of ocular surface squamous neoplasia using digital image
analysis. Oncol Lett. 8:1482–1486. 2014.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Kang YJ, Lee HB, Kim YG, Han J, Kim Y, Yoo
TK, Lee ES, Moon HG, Noh DY and Han W: Ki-67 expression is a
significant prognostic factor only when progesterone receptor
expression is low in estrogen receptor-positive and HER2-negative
early breast cancer. J Oncol. 2019(7386734)2019.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Silva LRD, Vargas RF, Shinzato JY,
Derchain SFM, Ramalho S and Zeferino LC: Association of menopausal
status, expression of progesterone receptor and Ki67 to the
clinical response to neoadjuvant chemotherapy in Luminal breast
cancer. Rev Bras Ginecol Obstet. 41:710–717. 2019.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Jain P, Doval DC, Batra U, Goyal P, Bothra
SJ, Agarwal C, Choudhary DK, Yadav A, Koyalla VPB, Sharma M, et al:
Ki-67 labeling index as a predictor of response to neoadjuvant
chemotherapy in breast cancer. Jpn J Clin Oncol. 49:329–338.
2019.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Li XR, Liu M, Zhang YJ, Wang JD, Zheng YQ,
Li J, Ma B and Song X: Evaluation of ER, PgR, HER-2, Ki-67, cyclin
D1, and nm23-H1 as predictors of pathological complete response to
neoadjuvant chemotherapy for locally advanced breast cancer. Med
Oncol. 28 (Suppl 1):S31–S38. 2011.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Røge R, Nielsen S, Riber-Hansen R and
Vyberg M: Ki-67 proliferation index in breast cancer as a function
of assessment method: A NordiQC experience. Appl Immunohistochem
Mol Morphol. 29:99–104. 2021.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Zhu X, Chen L, Huang B, Wang Y, Ji L, Wu
J, Di G, Liu G, Yu K, Shao Z and Wang Z: The prognostic and
predictive potential of Ki-67 in triple-negative breast cancer. Sci
Rep. 10(225)2020.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Radenkovic S, Milosevic Z, Konjevic G,
Karadzic K, Rovcanin B, Buta M, Gopcevic K and Jurisic V: Lactate
dehydrogenase, catalase, and superoxide dismutase in tumor tissue
of breast cancer patients in respect to mammographic findings. Cell
Biochem Biophys. 66:287–295. 2013.PubMed/NCBI View Article : Google Scholar
|
